|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15341535153615371538153915401541154215431544...15771578» |
- ||||| Turalio (pexidartinib) / Daiichi Sankyo
New P1/2 trial, Metastases: KEYNOTE-103: A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors (clinicaltrials.gov) - May 22, 2015
P1/2, N=400, Not yet recruiting, Sponsor: Plexxikon
- Enrollment change, Trial termination, Trial primary completion date: Adjuvant Valproate for High Grade Sarcomas (clinicaltrials.gov) - May 21, 2015
P1, N=7, Terminated, Sponsor: Columbia University
N=25 --> 7 | Recruiting --> Terminated | Trial primary completion date: Oct 2013 --> Feb 2014; Slow accrual
- sunitinib / Generic mfg.
Enrollment closed, Metastases: Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer (clinicaltrials.gov) - May 21, 2015
P2, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=25 --> 7 | Recruiting --> Terminated | Trial primary completion date: Oct 2013 --> Feb 2014; Slow accrual Recruiting --> Active, not recruiting
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2/3 trial: Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203) (clinicaltrials.gov) - May 20, 2015
P2/3, N=318, Recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Enrollment open: TRASTS: Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (clinicaltrials.gov) - May 20, 2015
P1/2, N=96, Recruiting, Sponsor: Grupo Espanol de Investigacion en Sarcomas
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P2 trial, Combination therapy, Metastases: A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas (clinicaltrials.gov) - May 19, 2015
P2, N=60, Not yet recruiting, Sponsor: Massachusetts General Hospital
- Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Enrollment open, Trial initiation date, Trial primary completion date, Surgery, Metastases: IRCI Gynae Sarcomas, High Grade Uterine Sarcoma (clinicaltrials.gov) - May 19, 2015
P2, N=78, Recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Jan 2014 --> Feb 2015 | Trial primary completion date: Jul 2017 --> Jul 2018
- sunitinib / Generic mfg.
Enrollment open, Metastases: Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer (clinicaltrials.gov) - May 19, 2015
P2, N=30, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Jan 2014 --> Feb 2015 | Trial primary completion date: Jul 2017 --> Jul 2018 Active, not recruiting --> Recruiting
- Lartruvo (olaratumab) / Eli Lilly
Enrollment closed, Metastases: A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - May 19, 2015
P1, N=24, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| imatinib / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator (clinicaltrials.gov) - May 19, 2015
P4, N=150, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=250 --> 150 | Trial primary completion date: Mar 2022 --> Sep 2023
- New trial, Circulating tumor DNA, Stroma: Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST) (clinicaltrials.gov) - May 14, 2015
P=N/A, N=60, Recruiting, Sponsor: Fondazione del Piemonte per l'Oncologia
- | Leukine (sargramostim) / Partner Therap, Reolysin (pelareorep) / Oncolytics, Andrus Reo
New P1 trial, Combination therapy: Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors (clinicaltrials.gov) - May 14, 2015
P1, N=21, Not yet recruiting, Sponsor: Mayo Clinic
- || Enrollment change: Collecting and Storing Biological Samples From Patients With Ewing Sarcoma (clinicaltrials.gov) - May 13, 2015
P=N/A, N=900, Recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting | N=250 --> 150 | Trial primary completion date: Mar 2022 --> Sep 2023 N=700 --> 900
- || Enrollment change: AREN03B2: Study of Kidney Tumors in Younger Patients (clinicaltrials.gov) - May 13, 2015
P=N/A, N=5000, Recruiting, Sponsor: Children's Oncology Group
N=700 --> 900 N=100 --> 5000
- New P1 trial: Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis (clinicaltrials.gov) - May 13, 2015
P1, N=15, Not yet recruiting, Sponsor: Kathy Miller
- || Enrollment closed: Protein Expression in Samples From Young Patients With Rhabdomyosarcoma (clinicaltrials.gov) - May 12, 2015
P=N/A, N=77, Active, not recruiting, Sponsor: Children's Oncology Group
N=100 --> 5000 Not yet recruiting --> Active, not recruiting
- ||| Biomarker, Trial completion: Biomarkers in Tissue Samples From Patients With Ewing Sarcoma (clinicaltrials.gov) - May 12, 2015
P=N/A, N=166, Completed, Sponsor: Children's Oncology Group
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Gilotrif (afatinib) / Boehringer Ingelheim
Enrollment open, Monotherapy, Pan tumor: Trial of Afatinib in Pediatric Tumours (clinicaltrials.gov) - May 12, 2015
P1, N=60, Recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment open: TAA-Specific CTLS for Solid Tumors (TACTASOM) (clinicaltrials.gov) - May 12, 2015
P1, N=18, Recruiting, Sponsor: Baylor College of Medicine
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment open: Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer (clinicaltrials.gov) - May 12, 2015
P=N/A, N=30, Recruiting, Sponsor: University of Wisconsin, Madison
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Biomarker, Enrollment closed: Biomarker Study in Samples From Patients With Malignant Rhabdoid Tumor of the Kidney or Atypical Teratoid Rhabdoid Tumor (clinicaltrials.gov) - May 12, 2015
P=N/A, N=20, Active, not recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- | Biomarker, Trial completion: Biomarkers in Predicting Response to Chemotherapy in Samples From Young Patients With Osteosarcoma (clinicaltrials.gov) - May 12, 2015
P=N/A, N=20, Completed, Sponsor: Children's Oncology Group
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Trial primary completion date: Studying Genes in Samples From Younger Patients With Rhabdomyosarcoma (clinicaltrials.gov) - May 8, 2015
P=N/A, N=58, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Trial primary completion date: Jun 2012 --> Jan 2100
- Trial primary completion date: Studying Gene Expression in Samples From Patients With Rhabdoid Tumors (clinicaltrials.gov) - May 8, 2015
P=N/A, N=25, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Jun 2012 --> Jan 2100 Trial primary completion date: May 2012 --> Jan 2100
- Biomarker, Trial primary completion date: Studying Biomarkers in Samples From Young Patients With Rhabdoid Tumors (clinicaltrials.gov) - May 8, 2015
P=N/A, N=50, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: May 2012 --> Jan 2100 Trial primary completion date: Apr 2012 --> Jan 2100
- ||| Biomarker, Enrollment open, Trial primary completion date: Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma (clinicaltrials.gov) - May 8, 2015
P=N/A, N=77, Recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Apr 2012 --> Jan 2100 Active, not recruiting --> Recruiting | Trial primary completion date: Feb 2012 --> Jan 2100
- || Biomarker, Trial primary completion date: DNA Biomarkers in Samples From Patients With Osteosarcoma and Healthy Volunteers (clinicaltrials.gov) - May 8, 2015
P=N/A, N=90, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Recruiting | Trial primary completion date: Feb 2012 --> Jan 2100 Trial primary completion date: Dec 2012 --> Jan 2100
- Trial primary completion date: Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients (clinicaltrials.gov) - May 8, 2015
P2, N=104, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2012 --> Jan 2100 Trial primary completion date: Nov 2015 --> Nov 2016
- ||| Enrollment open, Trial primary completion date: Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas (clinicaltrials.gov) - May 8, 2015
P=N/A, N=70, Recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Nov 2015 --> Nov 2016 Active, not recruiting --> Recruiting | Trial primary completion date: May 2012 --> Jan 2100
- ||| Enrollment open, Trial primary completion date: Study of Tumor Samples From Patients With Ewing Sarcoma (clinicaltrials.gov) - May 7, 2015
P=N/A, N=200, Recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Recruiting | Trial primary completion date: May 2012 --> Jan 2100 Active, not recruiting --> Recruiting | Trial primary completion date: Apr 2010 --> Jan 2100
- Avastin (bevacizumab) / Roche
Trial primary completion date: NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma (clinicaltrials.gov) - May 7, 2015
P2, N=40, Recruiting, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Recruiting | Trial primary completion date: Apr 2010 --> Jan 2100 Trial primary completion date: Apr 2015 --> Oct 2015
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Combination therapy, PD(L)-1 Biomarker, IO biomarker: NRG-BN002: Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma (clinicaltrials.gov) - May 7, 2015
P1, N=42, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Apr 2015 --> Oct 2015 Not yet recruiting --> Suspended
- sildenafil / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment change: Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers (clinicaltrials.gov) - May 7, 2015
P1, N=26, Active, not recruiting, Sponsor: Virginia Commonwealth University
Not yet recruiting --> Suspended N=50 --> 26
- cixutumumab (IMC A12) / Eli Lilly
Enrollment change, Metastases: Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - May 7, 2015
P1, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=50 --> 26 N=50 --> 30
- sirolimus / Generic mfg.
Enrollment open, Trial primary completion date: Studying Mechanisms of Radiation Therapy Resistance in Samples From Younger Patients With Rhabdomyosarcoma (clinicaltrials.gov) - May 7, 2015
P=N/A, N=20, Recruiting, Sponsor: Children's Oncology Group
N=50 --> 30 Active, not recruiting --> Recruiting | Trial primary completion date: Aug 2012 --> Jan 2100
- M032 / The University of Alabama
Enrollment closed: M032-HSV-1: Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma (clinicaltrials.gov) - May 7, 2015
P1, N=36, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Recruiting | Trial primary completion date: Aug 2012 --> Jan 2100 Recruiting --> Active, not recruiting
- Trial termination: Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research Protocols (clinicaltrials.gov) - May 6, 2015
P=N/A, N=767, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Completed --> Terminated
- Biomarker, Enrollment open, IO biomarker: Biomarker Differences in Samples From Patients With Undifferentiated Sarcomas (clinicaltrials.gov) - May 6, 2015
P=N/A, N=49, Recruiting, Sponsor: Children's Oncology Group
Completed --> Terminated Not yet recruiting --> Recruiting
- Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date, Surgery: Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - May 6, 2015
P=N/A, N=21, Recruiting, Sponsor: University of Washington
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2015 --> Apr 2016
- Zonalta (Z-endoxifen hydrochloride) / Jina Pharma, Intas
Trial primary completion date: Endoxifen in Adults With Hormone Receptor Positive Solid Tumors (clinicaltrials.gov) - May 6, 2015
P1, N=72, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Apr 2015 --> Apr 2016 Trial primary completion date: Apr 2015 --> Mar 2016
- Biomarker, Enrollment change, Metastases: Biomarkers in Patients With Advanced Rhabdomyosarcoma (clinicaltrials.gov) - May 6, 2015
P=N/A, N=10, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Apr 2015 --> Mar 2016 N=24 --> 10
- | Trial completion: Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM (clinicaltrials.gov) - May 6, 2015
P2, N=55, Completed, Sponsor: National Cancer Institute (NCI)
N=24 --> 10 Active, not recruiting --> Completed
- Trial initiation date, Trial primary completion date, HEOR: Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors (clinicaltrials.gov) - May 5, 2015
P=N/A, N=455, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Initiation date: Jan 2015 --> Jun 2015 | Trial primary completion date: Dec 2015 --> Mar 2016
- doxorubicin hydrochloride / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Post-Operative Chemoradiation for Extremity & Trunk Soft Tissue Sarcoma (clinicaltrials.gov) - May 5, 2015
P1, N=4, Completed, Sponsor: M.D. Anderson Cancer Center
Initiation date: Jan 2015 --> Jun 2015 | Trial primary completion date: Dec 2015 --> Mar 2016 Active, not recruiting --> Completed | N=36 --> 4 | Trial primary completion date: Jan 2017 --> Apr 2015
- Trial completion, Enrollment change, Trial primary completion date: Evaluation of Technetium Tc 99m Tilmanocept (Lymphoseek®) Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT and SPECT/CT Imaging (clinicaltrials.gov) - May 4, 2015
P2, N=5, Completed, Sponsor: Navidea Biopharmaceuticals
Active, not recruiting --> Completed | N=36 --> 4 | Trial primary completion date: Jan 2017 --> Apr 2015 Recruiting --> Completed | N=12 --> 5 | Trial primary completion date: Dec 2015 --> Mar 2015
- indoximod (NLG8189) / Lumos Pharma
Trial primary completion date: Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors (clinicaltrials.gov) - May 4, 2015
P1/2, N=18, Recruiting, Sponsor: NewLink Genetics Corporation
Recruiting --> Completed | N=12 --> 5 | Trial primary completion date: Dec 2015 --> Mar 2015 Trial primary completion date: Mar 2015 --> Dec 2015
- ||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1/2 trial: Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma (clinicaltrials.gov) - May 4, 2015
P1/2, N=99, Recruiting, Sponsor: Eisai Limited
- p53MVA - Tara I / O
New P1 trial, Combination therapy, PD(L)-1 Biomarker: Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov) - May 4, 2015
P1, N=12, Not yet recruiting, Sponsor: City of Hope Medical Center
- Trial completion, Enrollment change: Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research Protocols (clinicaltrials.gov) - May 1, 2015
P=N/A, N=767, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Mar 2015 --> Dec 2015 Recruiting --> Completed | N=3000 --> 767 | Recruiting --> Completed
- Trial primary completion date, MRI: Pilot Study: Dynamic Contrast-enhanced Magnetic Resonance Imaging(DCE-MRI)for Assessing Tumor Vascularity and Permeability in Soft Tissue Sarcoma Treated With Preoperative Radiotherapy Followed by Surgical Resection (clinicaltrials.gov) - May 1, 2015
P=N/A, N=16, Active, not recruiting, Sponsor: University of Utah
Recruiting --> Completed | N=3000 --> 767 | Recruiting --> Completed Trial primary completion date: Mar 2015 --> Mar 2017